 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P4 trial: Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Feb 28, 2024
P4, N=6080, Recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- || live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Clinical, Journal: Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study. (Pubmed Central) - Nov 15, 2022
Pathogenicity of shed vaccine virus to surrounding people was not observed. Thus, Phase Ⅱ study can be carried out as scheduled.
- ||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P2 trial: The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Mar 16, 2022
P2, N=2520, Not yet recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- ||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P1 trial: The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Sep 23, 2021
P1, N=160, Recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- ||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New trial: To Explore a Bridging Index for the Effectiveness of the Clinical Trial (clinicaltrials.gov) - Apr 1, 2021
P=N/A, N=450, Not yet recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- ||||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Trial completion, Trial primary completion date: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (clinicaltrials.gov) - Sep 14, 2017
P3, N=9000, Completed, Sponsor: Changchun BCHT Biotechnology Co.
Thus, Phase Ⅱ study can be carried out as scheduled. Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2017
- ||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Enrollment closed: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (clinicaltrials.gov) - Jan 24, 2017
P3, N=9000, Active, not recruiting, Sponsor: Changchun BCHT Biotechnology Co.
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2017 Recruiting --> Active, not recruiting
- || live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P3 trial: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (clinicaltrials.gov) - Nov 14, 2016
P3, N=9000, Recruiting, Sponsor: Changchun BCHT Biotechnology Co.